Prescient Therapeutics
Share Purchase Plan
This Offer Is Now Closed
Share Purchase Plan Details
Offer Price
TBA
*Offer is at the same price as the institutional placement
Share Purchase Plan Details
5 Day VWAP
$0.205*
Offer Price
$0.175
*This offer represents a 14.6% discount to the volume weighted average price (VWAP) over the 5 trading days before the date the SPP was announced. All applications and monies must be received by 5pm (AEDT) 4th October 2022.
Prescient is at the forefront of a booming revolution in cell therapy for oncology – forecast to grow from inception a few years ago to exceeding US$37 billion by 2028. We’re developing 4 blue-chip oncology assets that take a personalised medicine approach to cancer treatment to aim for superior patient outcomes. Our highly scalable business model and ability to enhance third party therapies gives us multiple shots at success and effectively a ‘shovels to the gold rush’ advantage in a burgeoning industry.
Steven Yatomi-Clarke
CEO and Managing Director
Speak to an adviser
By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.
Offer Details
Prescient Therapeutics Limited (ASX: PTX) has launched a Share Purchase Plan (SPP) targeting to raise $8,000,000 at $0.175/share, representing a discount of approximately 14.6% to Prescient’s 5-day VWAP (calculated on 23rd August 2022).
Use of Funds
The funds will be used to progress Prescient’s deep pipeline of innovative cancer therapies, namely the ongoing clinical development of its targeted therapies PTX-100 and PTX-200, and progressing its innovative cell therapies towards and into first-in-human clinical studies. Funds will also go towards general working capital and costs of the offer.
Latest News
Speak to an adviser
By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.
Any advice provided by Reach Markets, including on its website and by its representatives, is general advice only and does not consider your personal objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. You need to also read any relevant Prospectus or offer documents to understand the features, risks and returns associated with the investment to make your own informed decision. Please click here to read our full general advice warning. If you are thinking about acquiring a financial product, you should consider our Reach Markets Financial Services Guide (FSG) including the Privacy Statement. Past performance is not a reliable indicator of future performance.